Here’s why this pot stock gained a stunning 40% this morning

Nick Sundich Nick Sundich, October 3, 2023

As of 10.30am this morning, the biggest gaining ASX stock with news was pot stock ECS Botanics (ASX:ECS), all thanks to a $24m offtake deal.




Is this pot stock coming alive again?

The fortune of pot stocks rise and fall with changes in global regulations that investors anticipate will lead to the market being unlocked. They rise when changes are announced but then fall when investors realise that either it isn’t unlocked or even when it is, the company they thought would be in for a windfall is just a little fish in a big pond.

So it has been for ECS Botanics, a company that claims to be Australia’s largest B2B medicinal cannabis cultivator & manufacturer. But, today’s news was nothing to be snuffed at.


ECS Botanics share price chart, log scale (Source: TradingView)


ECS told its shareholders it secured a five year offtake deal with MediCann Health. This binding deal will see ECS supply MediCann with $24m of medicinal cannabis dried flower, starting in January 2024. This builds on an existing deals it has with MediCann that is worth $11.9m.


Is this pot stock for real?

ECS is certainly better poised than a company that has a non-binding MoU. But investors should remember that the medicinal cannabis industry is still relatively nascent and highly regulated, both in Australia and globally.

There is potential for long-term investors to make money if they back the right company, are prepared to deal with short-term volatility and wait for a few years. But not for short-term day traders trying to profit off the next regulatory change.


What are the Best biotech stocks to invest in right now?

Check our buy/sell stock tips


Recent Posts

buy nvidia shares in australia

Should you buy Nvidia shares in Australia?

Many investors are likely wondering if they should buy Nvidia shares in Australia? Others still might be wondering just who…


Mesoblast (ASX:MSB): Will it thrive or just survive in 2024?

Mesoblast’s (ASX:MSB) struggle with regenerative medicine in 2023 involved kеy financial movеs as wеll as opеrational rеstructurings. Thе entity which…

Star Entertainment Group … the house doesn’t always win

Thе recently released 2023 annual rеport of Star Entertainment Group portrays an intricatе fiscal position featuring extensive debt rеduction, but…